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S U M M A R Y
Objective: This study assessed the impact of annual versus biennial praziquantel treatment regimens on
the prevalence, intensity of infection, and liver ﬁbrosis dynamics of Asiatic schistosomiasis (caused by
Schistosoma japonicum) among individuals residing in 18 endemic barangays in Northern Samar,
Philippines.
Methods: Five hundred and sixty-ﬁve subjects who reported symptoms of gastrointestinal illness and/or
were believed to have clinical morbidity based on physical examination were selected for cohort follow-
up.
Results: The mean prevalence of schistosomiasis was 34% and the mean intensity of infection was
123.1 eggs per gram. Moderate to severe hepatic ﬁbrosis (grade II/III) was demonstrated in
approximately 25% of the study population. As expected, a greater reduction in both the prevalence
and intensity of infection was documented with two treatment rounds versus one. Overall, hepatic
ﬁbrosis (grades I–III) regressed in only 24.3% of those who received a single treatment and in only 19.3%
of those who received two doses. The prevalence of grade II–III ﬁbrosis at baseline (25.2%) remained
unchanged 2 years after treatment.
Conclusions: These ﬁndings suggest that in order to reverse moderate to severe liver ﬁbrosis due to
schistosomiasis and improve clinical outcomes, a higher clinical dosage of praziquantel (i.e., 60–80 mg/
kg) may be required over an extended duration.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
Schistosomiasis, a water-borne trematode disease, remains a
signiﬁcant public health problem. It affects over 240million people
worldwide, causing up to 70 million disability-adjusted life years
lost.1,2 [4_TD$DIFF] The World Health Organization (WHO) has recommended
and encouraged preventive chemotherapy as the chief strategy to
combat this tropical disease worldwide.3 Since the release of the
anti-schistosomal drug praziquantel (PZQ) for global use in 1979,* Corresponding author.
E-mail address: a.ross@grifﬁth.edu.au (Allen G.P. Ross).
http://dx.doi.org/10.1016/j.ijid.2016.10.001
1201-9712/ 2016 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).mass drug administration (MDA) has been relied on for the control
of schistosomiasis. Furthermore, theWHO decided to optimize the
PZQ dose by reducing it from 60 mg/kg given in two equal doses 3–
4 h apart to a single oral dose of 40 mg/kg, based on the results of a
series ofmulti-country clinical trials.3 Several studies have claimed
that preventive chemotherapy (i.e., 40 mg/kg PZQ), given once or
twice annually, can signiﬁcantly reduce the prevalence and
intensity of infection, and ensure the long-term control of
morbidity.3
In the Philippines, over 865 000 people are estimated to have
schistosomiasis, with another 12 million exposed to the disease.4,5
The poverty-stricken regions of the Visayas (Samar and Leyte) and
Mindanao are the main endemic foci (80%) in the country. Theseciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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Fig. 1. Study proﬁle and compliance among 18 221 residents from
22 schistosomiasis-endemic barangays in Palapag and Laoang, Northern Samar,
the Philippines. All inhabitants aged 5–65 years were invited to participate in the
study and provide two stool samples for parasitological examination. A subset of
patients (n = 736) were selected for ultrasound investigations.
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(villages). The existing national control programme involves
annual free MDA (40 mg/kg PZQ) in all schistosomiasis-endemic
communities with a prevalence of >10%. According to the
Philippines National Schistosomiasis Control Programme, the
recent human prevalence has dropped to less than 3% nation-
wide.5,6 However, contradictory reports have stated that the
programme is failing due to poor drug compliance, poor drug
coverage, irregular monitoring and evaluation, and rapid reinfec-
tion rates.4–6 Moreover, recently published data reported a very
high prevalence of the disease in both humans and bovines
throughout the country.4–6 Advanced schistosomiasis cases and
related deaths are currently being reported by the National
Department of Health for Mindanao, Samar, Leyte, and Oriental
Mindoro.6
Hepatic ﬁbrosis is the major cause of morbidity and mortality
among people with chronic schistosomiasis. Morbidity associated
with schistosomiasis includes variceal formation, splenomegaly,
and thrombocytopenia.7 Oesophageal and gastric variceal rupture
are the lethal outcomes of severe disease.8,9 The evaluation of
schistosomiasis-induced liver ﬁbrosis in the ﬁeld setting is best
made with a portable ultrasound (US).8 The device is reportedly
reliable and practical for detecting and assessing the degree of
schistosome-induced liver abnormalities, and for monitoring
pathological changes following chemotherapy.8 Several studies
over the past three decades have conﬁrmed its usefulness in
evaluating hepatosplenic schistosomiasis in the ﬁeld.8,10–13
In an earlier cross-sectional survey (2012) in the Philippines
involving 18 schistosomiasis-endemic barangays in Northern
Samar, an overall human prevalence of 27% was found.6 Further-
more, the morbidity assessment in the area using US showed that
liver ﬁbrosis occurred among 50% of the population. In this study,
the impact of annual versus biennial treatment on reversing the
prevalence and intensity of Schistosoma japonicum infection was
evaluated, as well as the schistosomiasis-induced morbidity.
2. Methods
2.1. Study area
Subjects from 18 endemic barangays in the municipalities of
Laoang and Palapag, Northern Samar, the Philippines, participated
in the study.7 Laoang and Palapag have had an active schistosomi-
asis control programme dating back to 1980. From 1980 to 1990,
the programme involved active case ﬁnding and directly observed
therapy (DOT) with 60 mg/kg PZQ given to all positive cases;
approximately 10–20% of the target population aged 5–65 years
was treated. The overall schistosomiasis prevalence ranged from
1% to 30% among the schistosomiasis-endemic barangays. From
1990 to 2007, case ﬁnding was strengthened to cover approxi-
mately 30–50% of the entire schistosomiasis-endemic population.
All egg-positive individuals again received DOT (60 mg/kg PZQ).
The schistosomiasis prevalence during this time ranged from 1% to
33% in the schistosomiasis-endemic barangays. In 2008, the MDA
DOT programme for schistosomiasis control commenced in the
study area and used 40 mg/kg PZQ, based on the recommendations
of both the National Department of Health and the WHO. All
individuals aged 5–65 years were offered 40 mg/kg PZQ annually,
free of charge, as per the Philippines Department of Health
Administrative Order 2007–0015. In the same year, the drug
compliance rate was high (70–85%), but it has declined signiﬁ-
cantly (25–65%) from 2009 to the present. The schistosomiasis
prevalence ranged from 1% to 46% in the schistosomiasis-endemic
barangays over this period. It is noteworthy that an individual can
be examined and, if found positive for schistosomiasis, treated for
free at any time of the year at a local health centre.2.2. Study procedures
The subjects who reported symptoms of gastrointestinal illness
and/or were believed to have clinical morbidity based on physical
examination were selected for cohort follow-up upon completion
of the cross-sectional survey in 2012 (Fig. 1).7 At baseline, the
prevalence and intensity of infection were determined by Kato–
Katz (KK) thick smear stool examination. Individuals were asked,
over the course of a week, to provide two stool specimens from
which six 50-g KK thick smears were prepared on microscope
slides according to established methods.14 [18_TD$DIFF] Slides were examined
under a light microscope in a designated barangay laboratory by
experienced technicians, who counted the number of S. japonicum
eggs per slide. For quality control, 10% of slides were randomly
selected and re-examined by a senior microscopist at the Research
Institute for Tropical Medicine, Manila. S. japonicum egg counts
were expressed as eggs per gram (epg) of stool.14 The intensity
of infection was graded according to WHO criteria: light infection
(1–99 epg), moderate infection (100–399 epg), and heavy infection
(400 epg).15
The degree of hepatic ﬁbrosis was assessed using a portable
gray-scale ultrasonogram equipped with a 3-MHz curve array
[(Fig._1)TD$FIG]
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Liver size was measured in millimetres along the Mid-sternal line
[20_TD$DIFF](MSL [21_TD$DIFF]) and[22_TD$DIFF]Mid-clavicular line [23_TD$DIFF](MCL[24_TD$DIFF]) for the left lobe and right lobe,
respectively. Spleen size was also measured in millimetres, along
the left mid-axillary line (MAL). The hepatic ﬁbrosis grading was
adopted from the practical guidelines established for ultrasonog-
raphy by the WHO/[25_TD$DIFF] ropical Disease Research (TDR [26_TD$DIFF]) (1990).16 [19_TD$DIFF] US
ﬁndings were arrived at by consensus agreement of two
experienced sonographers. Ten per cent of the US images were
independently validated by a radiologist.
Individuals found to be positive for schistosomiasis, apart from
pregnant women, were treated with oral DOT comprising 60 mg/
kg PZQ, following the Department of Health guidelines. More
speciﬁcally, egg-positive subjects were treated orally with 60 mg/
kg PZQ in two divided doses, followed by another treatment of the
same dose 2 weeks later. Stool-negative individuals were treated
with a single oral dose of 40 mg/kg. Following baseline assessment,
treatment follow-up was as follows: the ﬁrst cohort (group A;
n = 278) comprised subjects from 12 endemic barangays whowere
treated once after baseline assessment and followed-up 2 years
later (biennial treatment). The second cohort (group B; n = 159)
comprised individuals from six endemic barangays who were
treated twice, the ﬁrst time at baseline and then 1 year later, before
ﬁnal follow-up 2 years later (annual treatment).
All questionnaires were translated into the local dialect;
responses were back-translated into English. Ethical consent for
the study was obtained from the ethics review boards of the
Department of Health in the Philippines (Institutional Review
Board Number 2012-13-0) and Grifﬁth University, Australia.
Written informed consent was obtained from each individual, or
from the parents/legal guardians of those aged < 15 years.
2.3. Statistical analysis
Data were double-entered into FoxPro (version 6.0), cross-
checked, and subsequently analysed with STATA SE version
13.0 software (StataCorp LP, College Station, TX, USA). Data were
summarized as frequencies or as the mean  standard deviation
(SD), as appropriate. All categorical variables were evaluated using
the Chi-square test. TheWilcoxon signed rank test andMcNemar test
were used for paired analysis of the intensity of infection and
prevalence, respectively, across different age groups. With regards to
treatment impact on the intensity of infection, S. japonicum egg count
+ 1 was log10-transformed to bring observed distributions closer to
normality. A signiﬁcance level of 5%was used for statistical inference.
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Fig. 2. Cohort prevalence and intensity of infection with Schistosoma japonicum by3. Results
3.1. Study descriptors
Five hundred and sixty-ﬁve subjects were initially enrolled in
the study. Fifty-three percent of the study population was male,
and the mean age of the subjects was 39.4 years (95% conﬁdence
interval (CI) 38–41 years). Most were poor rice farmers with a
primary level of education and a high degree of water exposure.
There was no statistical difference in the sex proﬁle. However,
most of the study participants belonged to the age groups 36–45
years (24%) and 46–55 (27%) years. Only 1.0% of the population
reported having been diagnosed with hepatitis B; however, 38.4%
drank alcohol moderately (consumed 1–2 drinks per day).
3.2. Annual versus biennial PZQ treatment: impact on prevalence and
intensity of infection
The impact of treatment on the prevalence and intensity of
S. japonicum infection in group A (n = 278) and group B (n = 159)
was evaluated at baseline and at follow-up 2 years later
(Figs. 2 and 3). The initial prevalence of S. japonicum infection in
group A was 34.5% (n = 96/278; 95% CI 31.8–43.2%), and
intensity was 152.2 epg (95% CI 79.3–224.8). Two years after
treatment, the prevalence was reduced to 28.1% (n = 78/278;
95% CI 23.3–33.9%) and intensity to 121.0 epg (95% CI 52.1–
189.9). With regard to group B, the pre-treatment prevalence
was 32.1% (n = 51/159; 95% CI 24.8–39.3%) and intensity of
infection was 89.1 epg (95% CI 51.4–126.8). The prevalence was
reduced to 18.3% (n = 29/159; 95% CI 12.3–24.3%) and the
intensity of infection to 29.2 epg (95% CI 8.6–49.8) at 2 years
of follow-up. It is noteworthy that the initial prevalence of
infection of 40.0% among group B individuals aged 16–25 years
(n = 10) dropped to zero (p = 0.046). Signiﬁcant drops in the
intensity of infection were also observed only among group B
subjects aged 16–25 years (p = 0.047) and 46–55 years
(p = 0.004). Overall, signiﬁcant drops in prevalence in
both cohort groups were observed among individuals aged
16–25 years (p = 0.008) and 46–55 years (p = 0.001). On the
other hand, the overall intensity of infection across all age
categories decreased in both cohorts compared with pre-
treatment levels. Furthermore, only subjects aged 46–55 years
from both cohort groups showed signiﬁcant decreases in
intensity of infection compared with the baseline results
(p = 0.0028).0
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age, before (2012) and after (2015) one treatment of praziquantel (group A).
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Fig. 3. Cohort prevalence and intensity of infection with Schistosoma japonicum by age, before (2012) and after (2015) two treatments of praziquantel (group B).
Table 1
Dynamics of liver parenchyma grading before and after one dose (group A) or two doses (group B) of praziquantel treatment in Northern Samar, Philippines.
Parenchyma grading 2012 Liver parenchyma grading 2015 Total (n) Progressed Regressed
Normal Grade I Grade II Grade III
One dose of praziquantel
Normal 99 28 1 0 128 29 0
Grade I 30 24 7 5 66 12 30
Grade II 4 11 20 13 48 13 15
Grade III 2 1 13 6 22 0 16
Total (n) 135 64 41 24 264 54 61
Two doses of praziquantel
Normal 57 26 2 0 85 28 0
Grade I 10 16 10 2 38 12 10
Grade II 4 6 13 9 32 9 10
Grade III 0 0 1 4 5 0 1
Total (n) 71 48 26 15 160 49 21
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The impact of treatment on liver ﬁbrosis dynamicswas assessed
in both cohort groups (Tables 1 and 2). Compared with baseline,
20.5% (54/264) of groupA subjects had progression of parenchymal
ﬁbrosis, while 23.1% (49/264) had ﬁbrosis regression at follow-up.
With regard to group B, 30.6% (49/160) of the subjects progressed,
while only 13.3% (21/160) regressed at follow-up. The initial grade
II–III ﬁbrosis prevalence in group A was 26.5% (n = 70), but
decreased to 24.6% (n = 65) at follow-up. In contrast, the initial
grade II–III ﬁbrosis prevalence in group B was 23.1% (n = 37), but
increased to 25.6% (n = 41) at follow-up. Overall, the prevalence of
grade II–III ﬁbrosis among the 424 subjects at baseline was 25.2%Table 2
Liver parenchyma (grade II–III) dynamics by age at baseline and after treatment
(one versus two doses) with praziquantel.
Age, years With one treatment With two treatments
Number Liver
parenchyma
grade (II–III)
Number Liver
parenchyma
grade (II–III)
2012 2015 2012 2015
5–15 25 1 0 39 0 0
16–25 8 4 4 10 1 0
26–35 37 8 9 18 2 7
36–45 72 20 19 30 10 11
46–55 79 20 20 46 18 17
>55 43 17 13 17 6 6
Total 264 70 65 160 37 41(n = 107), but remained largely unchanged at 25.0% (n = 106) at
follow-up. As a whole, the prevalence of grade II–III ﬁbrosis
increased steadily with age.
4. Discussion
Although PZQ has proven to be safe and effective for the
treatment of schistosomiasis, it has certain limitations. PZQ is not
100% curative and does not prevent reinfection.17 It has no effect
on immature schistosomes, which may lower cure rates in areas
with very high levels of transmission.18,19
Based on the drug’s limitation in killing only adult worms,
Tukahebwa et al. performed a study to determine whether giving a
second dose increased the efﬁcacy against Schistosoma mansoni
infection in a highly endemic community in Mayuge District,
Uganda.20 This study, which compared one versus two PZQ doses
on cure rates for S. mansoni infection and reinfection, involved
395 subjects randomized to two groups: one received a single
standard dose of 40 mg/kg, while the other received a second dose
2 weeks later. The cure rate and intensity of infection were
evaluated 9weeks after the ﬁrst treatment, while reinfection levels
were monitored 8 and 24 months after treatment. The results
showed that those who were given the double dose of treatment
were more likely to be cured (69.7%) compared with those who
received only a single dose of PZQ (47.9%) (p < 0.001). However, at
endpoint, the difference in geometric mean intensity of reinfection
for those in the single-dose arm versus the two-dose arm was
insigniﬁcant. Hence it was suggested that two doses of PZQ
provided no added beneﬁt in terms of reduced reinfection rates.20
D.U. Olveda et al. / International Journal of Infectious Diseases 54 (2017) 145–149 149In contrast, King et al.21 reviewed the beneﬁts of repeated PZQ
dosing administered 2–8 weeks apart in Schistosoma-endemic
areas in Africa, and the results of this systematic review
demonstrated that treating children or communities with two
sequential doses of PZQ could be a cost-effective treatment plan for
areas with a high prevalence of S. mansoni or Schistosoma
haematobium, even in the face of ongoing transmission risk.
Another seeming advantage of the two-dose administration was
that more community subjects would be covered by giving them a
second chance of treatment.21
An earlier investigation (2012) by the present investigators in
the study area revealed that the baseline prevalence and intensity
of S. japonicum infection were high at 34% and 123.1 epg (95% CI
78.9–167.3), respectively.6,22 Furthermore, baseline US indicated
an alarmingly high level of schistosomiasis-induced liver morbidi-
ty: 88% of subjects had left lobe enlargement (70 mm) and 25%
had moderate to high (grade II–III) ﬁbrosis. These ﬁndings
suggested that the prevalence, intensity of infection, andmorbidity
had persisted in the endemic communities despite three decades
of human treatment and control carried out by the Municipal
Department of Health. These results were attributed to low drug
coverage (<36%), low drug compliance (<40%), and zoonotic
transmission (e.g., water buffalos and cattle acting as reservoir
hosts).23
In the current study, the impact of two treatment schedules
(one versus two rounds) on schistosomiasis prevalence, intensity
of infection, and hepatosplenic disease was assessed 2 years after
baseline curative treatment (i.e., a dose of 40–60 mg/kg PZQ). As
expected, the results showed greater reductions in both the
prevalence and intensity of infection with two treatment rounds
compared with one, especially among those aged 16–25 years and
46–55 years. However, treatment had less of an impact on
lowering schistosomiasis-induced morbidity. Overall, severe
hepatic ﬁbrosis (grades II–III) regressed in only 24.3% of those
who received a single treatment and in only 19.3% of those who
received two doses of PZQ. This outcome is similar to that reported
for S. japonicum morbidity in China.10
The present results also suggest that in order to reverse ﬁbrosis
and improve clinical outcomes among individuals with signiﬁcant
morbidity, a higher clinical dosage (i.e., 60–80 mg/kg) and longer
treatment duration may be required. The progression of ﬁbrosis in
a subset of individuals with hepatosplenic disease, despite
treatment, was also demonstrated. Some of these subjects might
belong to a small percentage of the population whose ﬁbrotic
lesions will eventually progress, regardless of treatment. Genetic
factors that regulate disease development may possibly account
for this outcome.24–26 Since not all of the population is subjected to
annual mass treatment, as evidenced by low drug coverage and
compliance,5,6,22 timely identiﬁcation of genetically susceptible
individuals may lead to improved clinical outcomes.
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